Commentary | Published:

Unraveling the autoimmune translational research process layer by layer

Nature Medicine volume 18, pages 3541 (2012) | Download Citation

Autoimmune diseases have a complex etiology and despite great progress having been made in our comprehension of these disorders, there has been limited success in the development of approved medications based on these insights. Development of drugs and strategies for application in translational research and medicine are hampered by an inadequate molecular definition of the human autoimmune phenotype and the organizational models that are necessary to clarify this definition.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    National Institutes of Health Research Portfolio Online Reporting Tools (2011).

  2. 2.

    American Autoimmune Related Disease Association. (2011).

  3. 3.

    N. Engl. J. Med. 347, 911–920 (2002).

  4. 4.

    National Human Genome Research Institute. (2011).

  5. 5.

    , , & Cell Host Microbe 3, 417–427 (2008).

  6. 6.

    Harv. Bus. Rev. (Nov-Dec): 61–78 (1996).

  7. 7.

    , & J. Am. Med. Assoc. 297, 403–406 (2007).

  8. 8.

    & Nat. Rev. Drug Discov. 3, 711–715 (2004).

  9. 9.

    Curr. Pharm. Biotechnol. 9, 423–430 (2008).

  10. 10.

    , , & Clin. Pharmacol. Ther. 87, 272–277 (2010).

  11. 11.

    , & Nat. Rev. Drug Discov. 9, 767–774 (2010).

  12. 12.

    & Annu. Rev. Med. 59, 1–12 (2008).

  13. 13.

    & Manage. Decis. Econ. 28, 469–479 (2007).

  14. 14.

    & Clin. Pharmacol. Ther. 89, 183–188 (2011).

  15. 15.

    Science 302, 63–72 (2003).

  16. 16.

    Sci. Transl. Med. 3, 90cm17 (2011).

  17. 17.

    , & QJM 101, 901–906 (2008).

  18. 18.

    Science 333, 819–821 (2011).

  19. 19.

    & J. Immunol. 172, 2731–2738 (2004).

  20. 20.

    Immunity 29, 835–838 (2008).

  21. 21.

    et al. Cell 134, 743–756 (2008).

  22. 22.

    , & Nat. Immunol. 8, 345–350 (2007).

  23. 23.

    et al. Ann. NY Acad. Sci. 1200, E1–E23 (2010).

  24. 24.

    , & Nat. Rev. Genet. 12, 56–68 (2011).

  25. 25.

    & Hum. Mol. Genet. 17, R116–R121 (2008).

  26. 26.

    et al. J. Allergy Clin. Immunol. 124, 1161–1178 (2009).

  27. 27.

    & J. Transl. Med. 2, 35 (2004).

  28. 28.

    et al. Nat. Genet. 37, 1217–1223 (2005).

  29. 29.

    et al. Science 326, 1694–1697 (2009).

  30. 30.

    & Acad. Med. 85, 457–462 (2010).

  31. 31.

    J. Clin. Invest. 121, 3778–3781 (2011).

  32. 32.

    & Sci. Transl. Med. 2, 53cm28 (2010).

  33. 33.

    J. Transl. Med. 2, 5 (2004).

  34. 34.

    & J. Clin. Invest. 119, 1061–1065 (2009).

  35. 35.

    & J. Exp. Med. 202, 1159–1162 (2005).

  36. 36.

    Nat. Biotechnol. 29, 3–4 (2011).

  37. 37.

    J. Am. Med. Assoc. 294, 1394–1398 (2005).

  38. 38.

    Nat. Rev. Drug Discov. 10, 321–322 (2011).

  39. 39.

    et al. J. Am. Med. Assoc. 289, 1278–1287 (2003).

  40. 40.

    J. Am. Med. Assoc. 294, 1390–1393 (2005).

  41. 41.

    N. Engl. J. Med. 354, 1665–1667 (2006).

  42. 42.

    et al. Science 296, 1401–1402 (2002).

  43. 43.

    & J. Am. Med. Assoc. 294, 1380–1384 (2005).

  44. 44.

    Thank you, Grover Norquist. Wall St. J. (22 November 22 2011).

  45. 45.

    The Congress of the United States Congressional Budget Office (October 2006).

  46. 46.

    et al. Targ. Oncol. 2, 113–119 (2007).

  47. 47.

    et al. Trends Mol. Med. 7, 201–204 (2001).

  48. 48.

    N. Engl. J. Med. 353, 1912–1925 (2005).

  49. 49.

    Nat. Rev. Drug Discov. 6, 99–101 (2007).

  50. 50.

    Nat. Rev. Drug Discov. 7, 107–109 (2008).

  51. 51.

    Nat. Rev. Drug Discov. 8, 93–96 (2009).

  52. 52.

    Nat. Rev. Drug Discov. 9, 89–92 (2010).

  53. 53.

    Nat. Rev. Drug Discov. 10, 82–85 (2011).

  54. 54.

    Nat. Med. 16, 1227–1232 (2010).

  55. 55.

    & Nat. Rev. Immunol. 10, 301–316 (2010).

  56. 56.

    & Nat. Rev. Immunol. 7, 715–725 (2007).

  57. 57.

    , , & Proc. Natl. Acad. Sci. USA 105, 19571–19578 (2008).

  58. 58.

    , & FEBS Lett. 585, 3699–3709 (2011).

  59. 59.

    et al. Nat. Biotechnol. 29, 615–624 (2011).

  60. 60.

    et al. Lancet 377, 721–731 (2011).

  61. 61.

    & Neurology 76, S3–S8 (2011).

  62. 62.

    Nature 324, 73–76 (1986).

  63. 63.

    Science 241, 825–828 (1988).

  64. 64.

    , , & J. Transl. Med. 2, 14 (2004).

  65. 65.

    , & Nat. Med. 11, 705–708 (2005).

  66. 66.

    , , & Clin. Sci. 112, 217–227 (2007).

  67. 67.

    Harv. Bus. Rev. (Jan-Feb): 103–116 (1981).

  68. 68.

    & Sci. Transl. Med. 2, 22cm9 (2010).

  69. 69.

    et al. Proc. Natl. Acad. Sci. USA 106, 8519–8524 (2009).

  70. 70.

    et al. Nat. Immunol. 11, 975–978 (2010).

  71. 71.

    & Arthritis Res. Ther. 13, 101 (2011).

  72. 72.

    , & J. Clin. Oncol. 28, e507–e510 (2010).

  73. 73.

    J. Clin. Oncol. 27, 2586–2588 (2009).

  74. 74.

    et al. Gut 60, 449–455 (2011).

  75. 75.

    & Gut 60, 430–431 (2011).

  76. 76.

    , & Trends Mol. Med. published online, doi:10.1016/j.molmed.2011.08.001 (30 September 2011).

  77. 77.

    , & Semin. Cancer Biol. 21, 267–275 (2011).

Download references

Acknowledgements

The authors thank T. Rath, C. Pola and L. Paradiso for assistance in assembling data related to recent approvals of therapeutic agents in autoimmunity and assembling the manuscript. R.S.B. was supported by US National Institutes of Health grants DK44319, DK53056, DK51362, DK88199 and the Harvard Digestive Diseases Center (grant DK34854). F.O.N. is supported by a Senior Investigator award of the National Institutes of Health Research, Wellcome Trust Programme grant GR078173MA, Medical Research Council UK Programme grant G0601387 and the UK Department of Health via the National Institute for Health Research comprehensive Biomedical Research Centre award to Guy's & St. Thomas' National Health Service Foundation Trust in partnership with King's College London.

Author information

Affiliations

  1. Richard S. Blumberg is at the Division of Gastroenterology and Hepatology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

    • Richard S Blumberg
  2. Bonnie Dittel is at the Blood Center of Wisconsin.

    • Bonnie Dittel
  3. David Hafler is at the Department of Neurology and Immunobiology, Yale University, New Haven, Connecticut, USA.

    • David Hafler
  4. Matthias von Herrath is at the La Jolla Institute of Allergy and Immunology, La Jolla, California, USA.

    • Matthias von Herrath
  5. Frank O. Nestle is at the St. John's Institute of Dermatology, King's College London and National Institute of Health Research (NIHR) Biomedical Research Centre Guy's and St. Thomas' Hospital, London, UK.

    • Frank O Nestle

Authors

  1. Search for Richard S Blumberg in:

  2. Search for Bonnie Dittel in:

  3. Search for David Hafler in:

  4. Search for Matthias von Herrath in:

  5. Search for Frank O Nestle in:

Competing interests

The authors declare no competing financial interests.

Corresponding author

Correspondence to Richard S Blumberg.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm.2632

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing